These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2276394)

  • 21. The metabolism of glyburide in subjects of known debrisoquin phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Clin Pharmacol Ther; 1989 Mar; 45(3):277-84. PubMed ID: 2493353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphic debrisoquin metabolism in a Turkish population.
    Bozkurt A; Basci NE; Isimer A; Sayal A; Kayaalp SO
    Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.
    Müller C; Siegmund W; Huupponen R; Kaila T; Franke G; Iisalo E; Zschiesche M
    Eur J Drug Metab Pharmacokinet; 1993; 18(3):265-72. PubMed ID: 8149945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
    Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
    Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG; Idle JR; Smith RL
    J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
    Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR
    Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine.
    Schoerlin MP; Blouin RA; Pfefen JP; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():98-100. PubMed ID: 2248089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
    Broly F; Vandamme N; Caron J; Libersa C; Lhermitte M
    Life Sci; 1991; 48(26):PL123-8. PubMed ID: 2046473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation.
    Karlaganis G; Küpfer A; Preisig R
    Br J Clin Pharmacol; 1984 Apr; 17(4):470-3. PubMed ID: 6721994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
    Llerena A; Alm C; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Apr; 14(2):92-7. PubMed ID: 1585408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK
    Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
    Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
    Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.